Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans. Anidulafungin selectively inhibits 1,3-β-D glucan synthase, an enzyme present in fungal, but not mammalian cells.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Anidulafungin is the active ingredient of these drugs:
Austria Brazil Cyprus Ecuador Estonia
Canada Hong Kong Singapore South Africa United States
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):